Intra portal donor specific antigen transfusion might prevent re-infection of hepatitis C virus after living related liver transplantation in hepatitis C hepatic cirrhosis

Hepato-Gastroenterology

Volumn 56, Issue 89, 2009, Pages 205-207

  Sato, Yoshinobu ^a   Oya, Hiroshi ^a   Yamamoto, Satoshi ^a   Kobayashi, Takashi ^a   Watanabe, Takaoki ^a   Kokai, Hidenaka ^a   Yamagiwa, Satoshi ^a   Hatakeyema, Katsuyoshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Donor specific transfusion; HCV re infection; Living related liver transplantation; Macrochimerism; Tolerance

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD56 ANTIGEN; FAS LIGAND; RIBAVIRIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REINFECTION; T LYMPHOCYTE; VIRUS IMMUNITY;

AGED; ANTIGENS, CD56; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMANS; KILLER CELLS, NATURAL; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; TRANSPLANTATION CHIMERA; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 64949186071     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Kokudo N: Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78:1308-1311.
2. Sato Y, Ichida T, Watanabe H, Yamamoto S, Abo T, Hatakeyama K: Macrochimerism of donor type CD56+CD3+T cells in donor specific transfusion via portal vein following living related donor liver transplantation. Hepato-Gastroenterol 2003; 50:2161-2165.
3. Sato Y, Ichida T, Watanabe H, Yamamoto S, Oya H, Nakatsuka H, Kobayashi T, Watanabe T, Kameyama H, Hatakeyama K: Repeating intraportal donor-specific transfusion may induce tolerance following adult living-related donor liver transplantation. Hepato-Gastroenterol 2003; 50:601-606.
4. Sato Y, Ichida T, Hatakeyama K: Real-time measurement of anti-HBs level and donor-specific transfusion via portal vein may reduce amount of HBIG after living related liver transplantation. Am J Gastroenterol. 2002; 97:488-489.
5. Yamagiwa S, Matsuda Y, Ichida T, Honda Y, Takamura M, Sugawara S, Ishikawa T, Ohkoshi S, Sato Y, Aoyagi Y: Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol Res. 2008; 38:664-672.